Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to - Business Industry Reports

Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to


  • May 2018
  • |
  • 189
  • |
  • Healthcare
  • |
  • IGATE Research

AlzheimerÂ’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from AlzheimerÂ’s disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.

Global AlzheimerÂ’s Disease Drugs Market and Pipeline Drugs Analysis

• In 2016, the global market for Alzheimer’s disease drugs was dominated by Namenda, Memary, Aricept and Exelon. The combined market share of these four drugs was over 80% in the year 2016.

• Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimer’s disease market.

• With the patent expiration of popular drugs the sales of the Alzheimer’s drugs have also declined. However, there are several pipeline drugs like Gantenerumab, Crenezumab and Aducanumab among others which are likely to hit the market during the period 2019 - 2020.

Global AlzheimerÂ’s Disease Country Wise Analysis

• In the Alzheimer’s disease drugs market, the United States is the largest market.

• Japan is the second leading market for Alzheimer’s disease drugs market accounting for XXX% market share in 2016.

• China stands at the third spot in the global Alzheimer’s disease drugs market being followed by India with XXX% share in the same year.

• The EU5 countries together accounted for over 10% share of the global Alzheimer’s disease drugs market in 2016.

iGATE RESEARCH report titled “Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021” is a 189 Page report with 74 Figures and 14 Tables. This report provides a comprehensive assessment of the Alzheimer’s Disease Drugs Market, Alzheimer’s Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer’s Disease - Country Wise Drugs Market, Country Wise Alzheimer’s Disease Prevalence, Major Deals in Alzheimer’s Disease Drugs Market Landscape, Funding in Alzheimer’s Disease Drugs Research, Driving Factors and Challenges for Alzheimer’s Disease Drugs Market.

The AlzheimerÂ’s Disease Drugs Market has been analyzed from 8 View Points:

1. AlzheimerÂ’s Disease - Drugs Sales and Forecast
2. AlzheimerÂ’s Disease - Pipeline Drugs Sales Forecast
3. AlzheimerÂ’s Disease Drugs - Country Wise Market and Forecast
4. AlzheimerÂ’s Disease - Country Wise Prevalence and Forecast
5. Alzheimer’s Disease – List of Pipeline Drugs in Various Phase of Development
6. AlzheimerÂ’s Disease - Major Deals in AlzheimerÂ’s Drugs Market
7. AlzheimerÂ’s Disease - Funding in AlzheimerÂ’s Disease Research
8. Alzheimer’s Disease Drugs Market – Driving Factors & Challenges

The Top 9 AlzheimerÂ’s Disease Drugs covered in the report are as follows:

1. Exelon
2. Razadyne/Reminyl
3. Memary
4. Ebixa
5. Aricept
6. Rivastach
7. Namenda
8. Nootropil
9. Namzaric

The 3 Pipeline AlzheimerÂ’s Disease Drugs covered in the report are as follows:

1. Gantenerumab
2. Crenezumab
3. Aducanumab

The 9 Countries AlzheimerÂ’s Disease Drugs Market covered in the report are as follows:

1. United States
2. France
3. Germany
4. Italy
5. Spain
6. United Kingdom
7. Japan
8. China
9. India

List of Pipeline AlzheimerÂ’s Disease Drugs in Various Phase of Development

1. Phase I
2. Phase II
3. Phase III

The AlzheimerÂ’s Disease Drugs Major Deals covered in the report are as follows:

1. Strategic Alliance
2. Licensing Agreement
3. Collaboration Deals
4. Mergers and Acquisitions

Data Source

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

1. Executive Summary

2. Global AlzheimerÂ’s Disease - Drugs Market and Prevalence Analysis

2.1 Global AlzheimerÂ’s Disease - Drugs Market and Forecast (2010 - 2021)
2.2 Global AlzheimerÂ’s Disease - Prevalence and Forecast (2010 - 2021)

3. Global AlzheimerÂ’s Disease - Country Wise Market Share and Forecast (2013 - 2021)

4. Global AlzheimerÂ’s Disease - Drugs Sales and Forecast To 2021

4.1 Exelon (Rivastigmine) Sales and Forecast
4.2 Razadyne/Reminyl Sales and Forecast
4.3 Memary (Memantine) Sales and Forecast
4.4 Ebixa (Memantine) Sales and Forecast
4.5 Aricept (Donepezil) Sales and Forecast
4.6 Rivastach Sales and Forecast
4.7 Namenda (Memantine) Sales and Forecast
4.8 Nootropil (Piracetam) Sales and Forecast
4.9 Namzaric (Memantine and Donepezil) Sales and Forecast

5. Global AlzheimerÂ’s Disease - Pipeline Drugs Analysis and Sales Forecast

5.1 Gantenerumab Drugs Analysis and Sales Forecast

5.1.1 About Gantenerumab
5.1.2 Clinical Trials
5.1.3 Gantenerumab Drugs Sales Forecast

5.2 Crenezumab Drugs Analysis and Sales Forecast

5.2.1 About Crenezumab
5.2.2 Clinical Trials
5.2.3 Crenezumab Drugs Sales Forecast

5.3 Aducanumab (BIIB037) Drugs Analysis and Sales Forecast

5.3.1 About BIIB037
5.3.2 Clinical Trials
5.3.3 Aducanumab (BIIB037) Drugs Sales Forecast

6. AlzheimerÂ’s Disease Drugs Market and Prevalence - Country Wise Analysis

6.1 United States - AlzheimerÂ’s Disease Drugs Market and Prevalence Analysis

6.1.1 United States - AlzheimerÂ’s Disease Drugs Market and Forecast (2013 - 2021)
6.1.2 United States - AlzheimerÂ’s Disease Prevalence and Forecast (2010 - 2021)

6.2 France - AlzheimerÂ’s Disease Drugs Market and Prevalence Analysis

6.2.1 France - AlzheimerÂ’s Disease Drugs Market and Forecast (2013 - 2021)
6.2.2 France - AlzheimerÂ’s Disease Prevalence and Forecast (2012 - 2021)

6.3 Germany - AlzheimerÂ’s Disease Drugs Market and Prevalence Analysis

6.3.1 Germany - AlzheimerÂ’s Disease Drugs Market and Forecast (2013 - 2021)
6.3.2 Germany - AlzheimerÂ’s Disease Prevalence and Forecast (2012 - 2021)

6.4 Italy - AlzheimerÂ’s Disease Drugs Market and Prevalence Analysis

6.4.1 Italy - AlzheimerÂ’s Disease Drugs Market and Forecast (2013 - 2021)
6.4.2 Italy - AlzheimerÂ’s Disease Prevalence and Forecast (2012 - 2021)

6.5 Spain - AlzheimerÂ’s Disease Drugs Market and Prevalence Analysis

6.5.1 Spain - AlzheimerÂ’s Disease Drugs Market and Forecast (2013 - 2021)
6.5.2 Spain - AlzheimerÂ’s Disease Prevalence and Forecast (2012 - 2021)

6.6 United Kingdom - AlzheimerÂ’s Disease Drugs Market and Prevalence Analysis

6.6.1 United Kingdom - AlzheimerÂ’s Disease Drugs Market and Forecast (2013 - 2021)
6.6.2 United Kingdom - AlzheimerÂ’s Disease Prevalence and Forecast (2012 - 2021)

6.7 Japan - AlzheimerÂ’s Disease Drugs Market and Prevalence Analysis

6.7.1 Japan - AlzheimerÂ’s Disease Drugs Market and Forecast (2013 - 2021)
6.7.2 Japan - AlzheimerÂ’s Disease Prevalence and Forecast (2012 - 2021)

6.8 China - AlzheimerÂ’s Disease Drugs Market and Prevalence Analysis

6.8.1 China - AlzheimerÂ’s Disease Drugs Market and Forecast (2013 - 2021)
6.8.2 China - AlzheimerÂ’s Disease Prevalence and Forecast (2010 - 2021)

6.9 India - AlzheimerÂ’s Disease Drugs Market and Prevalence Analysis

6.9.1 India - AlzheimerÂ’s Disease Drugs Market and Forecast (2013 - 2021)
6.9.2 India - AlzheimerÂ’s Disease Prevalence and Forecast (2010 - 2021)

7. Alzheimer's Disease Drug Development Pipeline: 2017

7.1 Agents Currently in Phase I of Alzheimer's Disease Drug Development (May 2017)
7.2 Agents Currently in Phase II of Alzheimer's Disease Drug Development (May 2017)
7.3 Agents Currently in Phase III of Alzheimer's Disease Drug Development (May 2017)
7.4 Immunotherapies in Clinical Trials for Alzheimer's Disease (May 2017)

8. Global AlzheimerÂ’s Disease Drugs Market - Major Deals Analysis

8.1 Global AlzheimerÂ’s Disease Drugs Market - Strategic Alliance
8.2 Global AlzheimerÂ’s Disease Drugs Market - Licensing Agreement
8.3 Global AlzheimerÂ’s Disease Drugs Market - Collaboration Deals
8.4 Global AlzheimerÂ’s Disease Drugs Market - Mergers and Acquisitions

9. Global AlzheimerÂ’s Disease Drugs Research - Funding Analysis

9.1 National Institute of Health (2011 - 2018)
9.2 Alzheimer's Association (2011 - 2016)
9.3 Cure AlzheimerÂ’s Fund (2008 - 2016)
9.4 AlzheimerÂ’s Drug Discovery Foundation (2008 - 2016)
9.5 BrightFocus Foundation (2010 - 2016)

10. Global AlzheimerÂ’s Disease Drug Market - Driving Factors

10.1 Growing Aging Population

10.1.1 Global Ageing Indicators
10.1.2 Population Aged 60 or Over: World and Development Regions, 1950 - 2050
10.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 - 2050

10.2 Unmet Medical Needs
10.3 Pipeline Candidate Expected to Drive AlzheimerÂ’s Disease Drugs Market
10.4 Future Drugs for Disease Modification in AlzheimerÂ’s Disease

11. Global AlzheimerÂ’s Disease Drug Market - Challenges

11.1 Lack of Validated Targets & Lack of Animal Models
11.2 Barriers in the Design and Implementation of Clinical Trials
11.3 Barriers in Academia & Regulatory Issues
11.4 AlzheimerÂ’s Drug Failure: Insinuation for Future R&D in Neuroscience
11.5 Costly AlzheimerÂ’s Drug Development Dissuade Drug Companies
11.6 Research Setbacks and Stepping Stones

11.7 Country Wise Barriers to Growth for AlzheimerÂ’s Disease Drugs Market

11.7.1 United States
11.7.2 France
11.7.3 Germany
11.7.4 United Kingdom
11.7.5 Japan
11.7.6 China
11.7.7 India

Sample Request is not available
Summary is not available